A Preclinical Research Scientist plays a crucial role in the transition from basic laboratory findings to clinical application. Their primary focus is evaluating the safety, efficacy, and biological behavior of drug candidates before they are tested in humans. This involves conducting a wide range of in vitro (cell-based) and in vivo (animal-based) experiments to understand how a compound interacts with the body and how the body processes it. Key areas of investigation include toxicity, pharmacokinetics (absorption, distribution, metabolism, and excretion), and pharmacodynamics (how the drug affects biological systems). These studies provide essential data for determining appropriate dosage levels and identifying potential risks.
Working at the interface of discovery and clinical development, Preclinical Research Scientists collaborate with toxicologists, pathologists, regulatory experts, and data scientists to design comprehensive study protocols. They generate detailed reports and interpret complex biological responses to assess whether a compound has a favorable safety margin for human testing. Regulatory guidelines, such as those from the FDA or EMA, shape much of their work to ensure that studies meet the rigorous standards required for Investigational New Drug (IND) applications. Advances in cell modeling, organ-on-chip technology, and predictive analytics are expanding the tools available for this critical stage. Their efforts are foundational in minimizing risk and ensuring that only the most promising and safe drug candidates move forward into clinical trials.
Title : The impact of metal-decorated polymeric nanodots on proton relaxivity
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : Hepatotoxic botanicals-shadows of pearls
Consolato M Sergi, Universities of Alberta and Ottawa, Canada
Title : Exploring classical ayurvedic drugs in hypertension
Prashant Bhokardankar, Datta Meghe Ayurved College, India
Title : Principles and standards for managing healthcare transformation towards personalized, preventive, predictive, participative precision medicine ecosystems
Bernd Blobel, University of Regensburg, Germany
Title : Personalized and Precision Medicine (PPM) as a unique healthcare model based on design-inspired biotech- & biopharma-driven applications to secure the human healthcare and biosafety
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : A unique role and and impact of catalytic antibodies (abzymes) in clinical practice: A novel strategy for predicting and preventing relapse in chronic autoimmune conditions
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : The promise of nanotechnology in personalized & precision medicine: Drug discovery & development being partnered with nanotechnologies via the revolution at the nanoscale
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : The promising future of the unique translational tool to manage beta-cell population renewal and regeneration to secure the post-diabetic period
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : Easily injectable, organic solvent free self assembled hydrogel platform for endoscope mediated gastrointestinal polypectomy
Hitasha Vithalani , IIT Gandhinagar, India
Title : Bridging tradition and innovation: Inorganic meets green synthesis
Maria Cristina Gamberini, University of Modena e Reggio Emilia, Italy